Abstract
Recently, it was observed that reverse-translocated cytosolic PrP and PrP expressed in the cytosol induce rapid death in neurons (Ma, J., Wollmann, R., and Lindquist, S. (2002) Science 298, 1781-1785). In this study, we investigated whether accumulation of prion protein (PrP) in the cytosol is toxic to human neurons in primary culture. We show that in these neurons, a single PrP isoform lacking signal peptide accumulates in the cytosol of neurons treated with epoxomicin, a specific proteasome inhibitor. Therefore, endogenously expressed PrP is subject to the endoplasmic reticulum-associated degradation (ERAD) pathway and is degraded by the proteasome in human primary neurons. In contrast to its toxicity in N2a cells, reverse-translocated PrP (ERAD-PrP) is not toxic even when neurons are microinjected with cDNA constructs to overexpress either wild-type PrP or mutant PrPD178N. We found that ERAD-PrP in human neurons remains detergent-soluble and proteinase K-sensitive, in contrast to its detergent-insoluble and proteinase K-resistant state in N2a cells. Furthermore, not only is microinjection of a cDNA construct expressing CyPrP not toxic, it protects these neurons against Bax-mediated cell death. We conclude that in human neurons, ERAD-PrP is not converted naturally into a form reminiscent of scrapie PrP and that PrP located in the cytosol retains its protective function against Bax. Thus, it is unlikely that simple accumulation of PrP in the cytosol can cause neurodegeneration in prion diseases.
Highlights
The prion protein (PrP)1 is mostly expressed as a secreted glycoprotein that remains attached to the cell surface through a glycophosphatidylinositol anchor
To assess whether PrP is subject to the endoplasmic reticulum associated protein degradation (ERAD) pathway in human neurons, we treated cells with both brefeldin A (BFA)
We show that endogenously expressed PrP is subject to the ERAD pathway in human primary neurons and that ERAD-PrP does not convert into a PrP scrapie (PrPSc)-like state in the presence of a proteasome inhibitor
Summary
PrP, prion protein; ERAD, endoplasmic reticulum-associated degradative pathway; ERAD-PrP, PrP derived from the ERAD and retro-translocated in the cytosol; SP-PrP, PrP containing the N-terminal signal peptide; PrPSc, PrP scrapie; CyPrP, cytosolic form of PrP (residues 23–231); EGFP, enhanced green fluorescent protein; DTR, dextran Texas Red; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling; BFA, brefeldin A; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; ER, endoplasmic reticulum; wtPrP, wild-type PrP. Wild-type and mutant PrPs, Y145stop and Q217R, respectively, generate intracellular PrP in the presence of proteasome inhibitors, indicating that the normally secreted PrP is subject to the degradative pathway termed endoplasmic reticulum associated protein degradation (ERAD), possibly to eliminate misfolded PrP molecules [2,3,4,5]. This form of PrP is termed ERAD-PrP. We conclude that accumulation of PrP in the cytosol of neurons is not sufficient for neurotoxicity
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have